Tony Kouzarides

Tony is Professor of Cancer Biology at the University of Cambridge, Deputy Director of the Gurdon Institute and Director of the Milner Therapeutics Institute.

Tony did his PhD at the University of Cambridge and postdoctoral work at MRC Laboratory of Molecular Biology on the cancer-inducing potential of human cytomegalovirus. He then went to NYU Medical Center in New York where he worked on the c-Fos onco-protein and the characterisation of the leucine zipper. He returned to Cambridge to lead a research group at the Gurdon Institute.

Tony is part of the Executive Board of the Cambridge Cancer Centre and on the Scientific Advisory Board of two Institutes on Spain (CRG in Barcelona and CABIMER in Seville). He is the founder and director of a cancer charity based in Spain, Vencer el Cancer (Conquer Cancer), which raises funds from the Spanish public to fund research on cancer.

Tony is a co-founder of Abcam plc (a publicly trading research reagents company) and a co-founder of two UK-based cancer drug discovery companies, Chroma Therapeutics (based in Oxford) and STORM Therapeutics (based in Cambridge).

Tony has been elected member of the European Molecular Biology organisation, is a Fellow of the British Academy of Medical Sciences (FMedSci), Fellow of the Royal Society (FRS) and is a Cancer Research UK Gibbs Fellow. He has been awarded the Wellcome Trust medal for research in biochemistry related to medicine (UK), the Tenovus Medal (UK), the Bodossaki Foundation prize in Biology (Greece), the Bijvoet Medal (Holland), the Biochemical Society Award Novartis Medal and Prize (UK) and the Heinrich Wieland Prize (Germany).